Dreesen E - Search Results

1

The effect of aging on infliximab exposure and response in patients with inflammatory bowel diseases.

Kantasiripitak W, Verstockt B, Alsoud D, Lobatón T, Thomas D, Gils A, Vermeire S, Ferrante M, Dreesen E. Kantasiripitak W, et al. Among authors: dreesen e. Br J Clin Pharmacol. 2021 Oct;87(10):3776-3789. doi: 10.1111/bcp.14785. Epub 2021 Mar 27. Br J Clin Pharmacol. 2021. PMID: 33604964 Free article.

2

Variability in Golimumab Exposure: A 'Real-Life' Observational Study in Active Ulcerative Colitis.

Detrez I, Dreesen E, Van Stappen T, de Vries A, Brouwers E, Van Assche G, Vermeire S, Ferrante M, Gils A. Detrez I, et al. Among authors: dreesen e. J Crohns Colitis. 2016 May;10(5):575-81. doi: 10.1093/ecco-jcc/jjv241. Epub 2016 Jan 6. J Crohns Colitis. 2016. PMID: 26738756 Free PMC article.

3

Pharmacokinetic Modeling and Simulation of Biologicals in Inflammatory Bowel Disease: The Dawning of a New Era for Personalized Treatment.

Dreesen E, Gils A, Vermeire S. Dreesen E, et al. Curr Drug Targets. 2018;19(7):757-776. doi: 10.2174/1389450117666160307144329. Curr Drug Targets. 2018. PMID: 26953243 Review.

4

Harmonization of Infliximab and Anti-Infliximab Assays Facilitates the Comparison Between Originators and Biosimilars in Clinical Samples.

Gils A, Van Stappen T, Dreesen E, Storme R, Vermeire S, Declerck PJ. Gils A, et al. Among authors: dreesen e. Inflamm Bowel Dis. 2016 Apr;22(4):969-75. doi: 10.1097/MIB.0000000000000709. Inflamm Bowel Dis. 2016. PMID: 26954707

5

A Genetic Variation in the Neonatal Fc-Receptor Affects Anti-TNF Drug Concentrations in Inflammatory Bowel Disease.

Billiet T, Dreesen E, Cleynen I, Wollants WJ, Ferrante M, Van Assche G, Gils A, Vermeire S. Billiet T, et al. Among authors: dreesen e. Am J Gastroenterol. 2016 Oct;111(10):1438-1445. doi: 10.1038/ajg.2016.306. Epub 2016 Aug 2. Am J Gastroenterol. 2016. PMID: 27481307

6

Blocking α4β7 Integrin Through Vedolizumab: Necessary but not Sufficient?

Dreesen E, Gils A. Dreesen E, et al. J Crohns Colitis. 2017 Aug 1;11(8):903-904. doi: 10.1093/ecco-jcc/jjx033. J Crohns Colitis. 2017. PMID: 28333273 No abstract available.

7

Practical recommendations for the use of therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases.

Dreesen E, Bossuyt P, Mulleman D, Gils A, Pascual-Salcedo D. Dreesen E, et al. Clin Pharmacol. 2017 Oct 3;9:101-111. doi: 10.2147/CPAA.S138414. eCollection 2017. Clin Pharmacol. 2017. PMID: 29042821 Free PMC article. Review.

8

Antibodies Toward Vedolizumab Appear from the First Infusion Onward and Disappear Over Time.

Bian S, Dreesen E, Tang HT, Compernolle G, Peeters M, Van Assche G, Ferrante M, Vermeire S, Gils A. Bian S, et al. Among authors: dreesen e. Inflamm Bowel Dis. 2017 Dec;23(12):2202-2208. doi: 10.1097/MIB.0000000000001255. Inflamm Bowel Dis. 2017. PMID: 29140943

9

Anti-infliximab antibody concentrations can guide treatment intensification in patients with Crohn's disease who lose clinical response.

Dreesen E, Van Stappen T, Ballet V, Peeters M, Compernolle G, Tops S, Van Steen K, Van Assche G, Ferrante M, Vermeire S, Gils A. Dreesen E, et al. Aliment Pharmacol Ther. 2018 Feb;47(3):346-355. doi: 10.1111/apt.14452. Epub 2017 Dec 11. Aliment Pharmacol Ther. 2018. PMID: 29226370

10

Evidence to Support Monitoring of Vedolizumab Trough Concentrations in Patients With Inflammatory Bowel Diseases.

Dreesen E, Verstockt B, Bian S, de Bruyn M, Compernolle G, Tops S, Noman M, Van Assche G, Ferrante M, Gils A, Vermeire S. Dreesen E, et al. Clin Gastroenterol Hepatol. 2018 Dec;16(12):1937-1946.e8. doi: 10.1016/j.cgh.2018.04.040. Epub 2018 Apr 25. Clin Gastroenterol Hepatol. 2018. PMID: 29704680

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

113 results

Search Page

Filters